Meeting
2016 ASCO Annual Meeting
Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer.
Authors
Kyriakos P. Papadopoulos
START Center for Cancer Care, San Antonio, TX
Kyriakos P. Papadopoulos , Aung Naing , Jeffrey R. Infante , Karen A. Autio , Patrick Alexander Ott , Deborah Jean Lee Wong , Gerald Steven Falchook , Manish R. Patel , Shubham Pant , Melinda Whiteside , John B Mumm , Ivan H Chan , Johanna C. Bendell , Drew W. Rasco , Kent C. Shih , Milind M. Javle , Todd Michael Bauer , Rivka R Colen , Peter Van Vlasselaer , Martin Oft
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Other
Clinical Trial Registration Number
NCT02009449
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3082)
DOI
10.1200/JCO.2016.34.15_suppl.3082
Abstract #
3082
Poster Bd #
404
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
First Author: J. Randolph Hecht
Poster
2018 ASCO Annual Meeting
Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
First Author: J. Randolph Hecht
Poster
2017 ASCO Annual Meeting
PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA‑4 refractory melanoma.
First Author: Aung Naing
Poster
2017 ASCO Annual Meeting
Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer.
First Author: Aung Naing